In a model applying SELECT trial estimates to MESA adults without diabetes or CVD, the 5-year number needed to treat with semaglutide for MACE was 653 with CAC = 0 and 79 with CAC of 300 or more.
In plain wordsIn a model, semaglutide needs fewer patients with high coronary calcium than with none to prevent one major heart event over 5 years.
- Peptide
- Semaglutide
- Outcome
- Not applicable5-year number needed to treat with semaglutide for MACE
- Study
humann = 3,129
SELECT risk reduction estimates applied to MESA participants- Comparator
- CAC = 0 versus CAC >= 300
- Outcome group
- Cardiovascular events · Cardiovascular
Measurements
- 5-year number needed to treat
- 653
- CAC = 0, MACE
- 5-year number needed to treat
- 79
- CAC >=300, MACE
Source sentences
for MACE (653 vs 79)
2 context sentences(design, population, supporting numbers)
In this analysis, 3,129 participants in the MESA (Multi-Ethnic Study of Atherosclerosis) without diabetes or clinical CVD met body mass index criteria for semaglutide and underwent CAC scoring on noncontrast cardiac computed tomography.
Risk reduction estimates from the SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) trial (median follow-up: 3.3 years) were applied to observed incidence rates for semaglutide 5-year number-needed-to-treat calculations.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.